Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma
Open Access
- 22 February 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 28 (9) , 1881-1895
Abstract
Purpose: Novel therapeutic targets are critical to unravel for the most common primary brain tumor in adults, glioblastoma (GBM). We have identified a novel synthetic lethal interaction between ClpP activation and HDAC1/2 inhibition that converges on GBM energy metabolism. Experimental Design: Transcriptome, metabolite, and U-13C-glucose tracing analyses were utilized in patient-derived xenograft (PDX) models of GBM. Orthotopic GBM models were used for in vivo studies. Results: We showed that activation of the mitochondrial ClpP protease by mutant ClpP (Y118A) or through utilization of second-generation imipridone compounds (ONC206 and ONC212) in combination with genetic interference of HDAC1 and HDAC2 as well as with global (panobinostat) or selective (romidepsin) HDAC inhibitors caused synergistic reduction of viability in GBM model systems, which was mediated by interference with tricarboxylic acid cycle activity and GBM cell respiration. This effect was partially mediated by activation of apoptosis along with activation of caspases regulated chiefly by Bcl-xL and Mcl-1. Knockdown of the ClpP protease or ectopic expression of a ClpP D190A mutant substantially rescued from the inhibition of oxidative energy metabolism as well as from the reduction of cellular viability by ClpP activators and the combination treatment, respectively. Finally, utilizing GBM PDX models, we demonstrated that the combination treatment of HDAC inhibitors and imipridones prolonged host survival more potently than single treatments or vehicle in vivo. Conclusions: Collectively, these observations suggest that the efficacy of HDAC inhibitors might be significantly enhanced through ClpP activators in model systems of human GBM.Keywords
All Related Versions
Funding Information
- Cancer Center Flow Core Facility (P30CA013696, S10RR027050)
- CTSA (UL1-TR001430)
- Boston University Microarray and Sequencing Resource Core Facility
- Columbia University Medical Center Cancer
- NIH (#P30 CA013696)
- NIH NINDS (R01NS095848, R01NS102366, R01NS113793)
- American Brain Tumor Association Discovery (DG1700013)
- American Brain Tumor Association Discovery (DG2100041)
- Nguyen: American Brain Tumor Association Basic Research (BRF1900018)
- Salveena Schiffgens: Fritz Thyssen Foundation (40.19.0.016MN)
This publication has 36 references indexed in Scilit:
- MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic CancerCancer Cell, 2017
- ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent MechanismsMolecular Cancer Therapeutics, 2017
- Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trialThe Lancet Oncology, 2017
- Transcriptional Dependencies in Diffuse Intrinsic Pontine GliomaCancer Cell, 2017
- Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitorsJournal of Clinical Investigation, 2016
- Erratum: Functionally defined therapeutic targets in diffuse intrinsic pontine gliomaNature Medicine, 2015
- The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activityOncotarget, 2014
- Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor EffectsScience Translational Medicine, 2013
- An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent PathwayCancer Discovery, 2011
- A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03Neuro-Oncology, 2011